venBio Global Strategic Fund IV, L.P., 10% Owner at Attovia Therapeutics, Inc. (ATTO), bought 382,352 shares at $17.00 ($6.5M) on 2026-08-06, disclosed to the SEC on 2026-08-10.
VenBio Global Strategic Fund IV, L.P. executed a $6.5M purchase of 382,352 shares at $17.00, marking the largest insider purchase in the company's history and signaling strong conviction in the biotech's valuation.
The stock is currently trading at $19.785, sitting 13.03% below its 52-week high of $22.75 and 4.35% above its 52-week low of $18.96.
Insider momentum: The purchase is the largest ever recorded for the company, with a pit cluster size of 2 indicating other insiders bought recently; track this momentum.
Valuation risk: The stock is trading 13.03% below its 52-week high, suggesting the market may be pricing in significant downside or uncertainty despite the recent insider buying.
Negative factors outweigh the positive ones.